- Home
- DMA vs KZIA Comparison
DMA vs KZIA Comparison
Compare DMA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMA | KZIA |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.8M | 74.4M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | DMA | KZIA |
|---|---|---|
| Price | $9.00 | $7.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 34.6K | ★ 257.7K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.78 | $2.86 |
| 52 Week High | $8.00 | $17.40 |
Technical Indicators
Market Signals| Indicator | DMA | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 51.37 | 45.05 |
| Support Level | $9.00 | $6.07 |
| Resistance Level | $9.15 | $7.41 |
| Average True Range (ATR) | 0.12 | 0.77 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 50.00 | 81.52 |
Price Performance
Historical ComparisonAbout DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.